#USA #New Orleans #Type 2 Diabetes #Continuous Glucose Monitoring #A1C Reduction

Introduction

In a groundbreaking new study presented at the 2026 Scientific Sessions of the American Diabetes Association, researchers revealed some promising findings about continuous glucose monitoring (CGM) in the management of type 2 diabetes, specifically among adults who do not use insulin. The study confirms what many in the medical community suspected: CGM can significantly reduce hyperglycemia and improve overall blood glucose control.

Study Overview

Conducted across 22 diverse primary care practices in the United States, the CONNECT randomized controlled trial involved 283 adults aged around 60 years, with various racial and ethnic backgrounds. Participants had diagnosed A1C levels ranging from 7.1% to 14.9% and were using oral medications, such as SGLT2 inhibitors and incretin-based therapies. They were randomly assigned to two groups: one receiving CGM (specifically the Dexcom G7 device) and the other continuing with standard blood glucose meter testing.

The primary focus of the study was to assess the reduction in A1C levels, a key indicator of long-term glucose management, after a 26-week period. Participants initially faced an average A1C of 8.8%, with 31% exhibiting A1C levels over 9%, suggesting a high prevalence of uncontrolled diabetes among the cohort.

Key Findings

The results were striking. Patients utilizing the CGM demonstrated a 0.9% greater reduction in A1C levels compared to those receiving routine care alone. More importantly, those in the CGM group spent an impressive five hours more each day within the optimal glucose target range of 70 to 180 mg/dL. Such improvements in sugar management not only indicate better glycemic control, but also reflect enhanced satisfaction among participants regarding their health management, leading to decreased emotional distress related to their diagnosis.

Implications for Diabetes Care

Dr. Thomas W. Martens, a co-author of the study, emphasized that many type 2 diabetes patients depend on non-insulin therapies in primary care settings. By incorporating CGM into their management plans, healthcare providers have a significant opportunity to address the existing care gap for these patients. As CGM technology continues to evolve, the positive outcomes of this study may drive changes in diabetes care protocols, leading to more informed decision-making and treatment options across various healthcare environments.

Next Steps in Research

The research does not end here. An extension phase of the trial is underway, promising additional data regarding the long-term sustainability of CGM benefits beyond the initial monitoring period. With ongoing assessments, healthcare practitioners will gain crucial insights into how best to implement CGM technology effectively within varied practice settings, thereby optimizing outcomes for chronic disease management.

Conclusion

As the landscape of diabetes management continues to transform through innovative technology and research, findings from the CONNECT trial signal an optimistic direction. Embracing continuous glucose monitoring could represent a vital step forward in managing type 2 diabetes, especially for those not using insulin therapy. The implications heralded by this study could significantly improve health outcomes for millions of people living with diabetes, granting them more control over their health journeys.